| VR-CAP | R-CHOP | Differencea |
---|---|---|---|
Deterministic results | |||
 QALYs | 4.10 | 3.29 | 0.81 |
  Progression-free survival from first-line treatment | 2.70 | 1.54 | 1.16 |
  Progressed from first-line treatment | 0.14 | 0.10 | 0.03 |
  Progression-free survival from second-line treatment | 0.12 | 0.15 | −0.03 |
  Progressed from second-line treatment | 1.15 | 1.50 | −0.35 |
 Costs | £45,842 | £29,630 | £16,212 |
  First line therapy medication costs | £22,606 | £8,041 | £14,566 |
  Administration of first line therapy | £5,817 | £1,564 | £4,253 |
  Adverse events, transfusions & concomitant medication | £1,472 | £1,105 | £367 |
  Disease management costs | £4,191 | £4,676 | −£486 |
  Second line treatment (medication and administration) | £7,152 | £9,423 | −£2,271 |
  Terminal care | £4,605 | £4,821 | −£217 |
 Deterministic ICER (£/QALY gained) |  |  | £20,043 |
Probabilistic results | Â | Â | Â |
 QALYs | 4.09 | 3.28 | 0.81 |
 Costs | £45,482 | £29,285 | £16,196 |
Probabilistic ICER (£/QALY gained) |  |  | £19,889 |